HV Bushing
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global IBS Treatment Market Research Report 2023
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 IBS-D
1.2.3 IBS-C
1.2.4 IBS-M
1.3 Market by Application
1.3.1 Global IBS Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global IBS Treatment Market Perspective (2017-2028)
2.2 IBS Treatment Growth Trends by Region
2.2.1 IBS Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 IBS Treatment Historic Market Size by Region (2017-2022)
2.2.3 IBS Treatment Forecasted Market Size by Region (2023-2028)
2.3 IBS Treatment Market Dynamics
2.3.1 IBS Treatment Industry Trends
2.3.2 IBS Treatment Market Drivers
2.3.3 IBS Treatment Market Challenges
2.3.4 IBS Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top IBS Treatment Players by Revenue
3.1.1 Global Top IBS Treatment Players by Revenue (2017-2022)
3.1.2 Global IBS Treatment Revenue Market Share by Players (2017-2022)
3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by IBS Treatment Revenue
3.4 Global IBS Treatment Market Concentration Ratio
3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2021
3.5 IBS Treatment Key Players Head office and Area Served
3.6 Key Players IBS Treatment Product Solution and Service
3.7 Date of Enter into IBS Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IBS Treatment Breakdown Data by Type
4.1 Global IBS Treatment Historic Market Size by Type (2017-2022)
4.2 Global IBS Treatment Forecasted Market Size by Type (2023-2028)
5 IBS Treatment Breakdown Data by Application
5.1 Global IBS Treatment Historic Market Size by Application (2017-2022)
5.2 Global IBS Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America IBS Treatment Market Size (2017-2028)
6.2 North America IBS Treatment Market Size by Country (2017-2022)
6.3 North America IBS Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe IBS Treatment Market Size (2017-2028)
7.2 Europe IBS Treatment Market Size by Country (2017-2022)
7.3 Europe IBS Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific IBS Treatment Market Size (2017-2028)
8.2 Asia-Pacific IBS Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific IBS Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America IBS Treatment Market Size (2017-2028)
9.2 Latin America IBS Treatment Market Size by Country (2017-2022)
9.3 Latin America IBS Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa IBS Treatment Market Size (2017-2028)
10.2 Middle East & Africa IBS Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa IBS Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Allergan (Ireland)
11.1.1 Allergan (Ireland) Company Detail
11.1.2 Allergan (Ireland) Business Overview
11.1.3 Allergan (Ireland) IBS Treatment Introduction
11.1.4 Allergan (Ireland) Revenue in IBS Treatment Business (2017-2022)
11.1.5 Allergan (Ireland) Recent Development
11.2 Sucampo Pharmaceuticals (U.S.)
11.2.1 Sucampo Pharmaceuticals (U.S.) Company Detail
11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
11.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
11.3 Ironwood Pharmaceuticals (U.S.)
11.3.1 Ironwood Pharmaceuticals (U.S.) Company Detail
11.3.2 Ironwood Pharmaceuticals (U.S.) Business Overview
11.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Introduction
11.3.4 Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.3.5 Ironwood Pharmaceuticals (U.S.) Recent Development
11.4 Astellas Pharma (Japan)
11.4.1 Astellas Pharma (Japan) Company Detail
11.4.2 Astellas Pharma (Japan) Business Overview
11.4.3 Astellas Pharma (Japan) IBS Treatment Introduction
11.4.4 Astellas Pharma (Japan) Revenue in IBS Treatment Business (2017-2022)
11.4.5 Astellas Pharma (Japan) Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Detail
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health IBS Treatment Introduction
11.5.4 Bausch Health Revenue in IBS Treatment Business (2017-2022)
11.5.5 Bausch Health Recent Development
11.6 Abbott Laboratories (U.S.)
11.6.1 Abbott Laboratories (U.S.) Company Detail
11.6.2 Abbott Laboratories (U.S.) Business Overview
11.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
11.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.6.5 Abbott Laboratories (U.S.) Recent Development
11.7 Synergy Pharmaceuticals (U.S.)
11.7.1 Synergy Pharmaceuticals (U.S.) Company Detail
11.7.2 Synergy Pharmaceuticals (U.S.) Business Overview
11.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Introduction
11.7.4 Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.7.5 Synergy Pharmaceuticals (U.S.) Recent Development
11.8 Ardelyx (U.S.)
11.8.1 Ardelyx (U.S.) Company Detail
11.8.2 Ardelyx (U.S.) Business Overview
11.8.3 Ardelyx (U.S.) IBS Treatment Introduction
11.8.4 Ardelyx (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.8.5 Ardelyx (U.S.) Recent Development
11.9 Nestle (Switzerland)
11.9.1 Nestle (Switzerland) Company Detail
11.9.2 Nestle (Switzerland) Business Overview
11.9.3 Nestle (Switzerland) IBS Treatment Introduction
11.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2017-2022)
11.9.5 Nestle (Switzerland) Recent Development
11.10 Sebela Pharmaceuticals (Ireland)
11.10.1 Sebela Pharmaceuticals (Ireland) Company Detail
11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
11.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2017-2022)
11.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
11.11 Probi (Sweden)
11.11.1 Probi (Sweden) Company Detail
11.11.2 Probi (Sweden) Business Overview
11.11.3 Probi (Sweden) IBS Treatment Introduction
11.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2017-2022)
11.11.5 Probi (Sweden) Recent Development
11.12 Alfasigma USA (Italy)
11.12.1 Alfasigma USA (Italy) Company Detail
11.12.2 Alfasigma USA (Italy) Business Overview
11.12.3 Alfasigma USA (Italy) IBS Treatment Introduction
11.12.4 Alfasigma USA (Italy) Revenue in IBS Treatment Business (2017-2022)
11.12.5 Alfasigma USA (Italy) Recent Development
11.13 RedHill Biopharma (Israel)
11.13.1 RedHill Biopharma (Israel) Company Detail
11.13.2 RedHill Biopharma (Israel) Business Overview
11.13.3 RedHill Biopharma (Israel) IBS Treatment Introduction
11.13.4 RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2017-2022)
11.13.5 RedHill Biopharma (Israel) Recent Development
11.14 AstraZeneca (U.K)
11.14.1 AstraZeneca (U.K) Company Detail
11.14.2 AstraZeneca (U.K) Business Overview
11.14.3 AstraZeneca (U.K) IBS Treatment Introduction
11.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2017-2022)
11.14.5 AstraZeneca (U.K) Recent Development
11.15 Ipsen (France)
11.15.1 Ipsen (France) Company Detail
11.15.2 Ipsen (France) Business Overview
11.15.3 Ipsen (France) IBS Treatment Introduction
11.15.4 Ipsen (France) Revenue in IBS Treatment Business (2017-2022)
11.15.5 Ipsen (France) Recent Development
11.16 Novartis (Switzerland)
11.16.1 Novartis (Switzerland) Company Detail
11.16.2 Novartis (Switzerland) Business Overview
11.16.3 Novartis (Switzerland) IBS Treatment Introduction
11.16.4 Novartis (Switzerland) Revenue in IBS Treatment Business (2017-2022)
11.16.5 Novartis (Switzerland) Recent Development
11.17 Takeda Pharmaceutical Company (Japan)
11.17.1 Takeda Pharmaceutical Company (Japan) Company Detail
11.17.2 Takeda Pharmaceutical Company (Japan) Business Overview
11.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Introduction
11.17.4 Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2017-2022)
11.17.5 Takeda Pharmaceutical Company (Japan) Recent Development
11.18 Synthetic Biologics (U.S.)
11.18.1 Synthetic Biologics (U.S.) Company Detail
11.18.2 Synthetic Biologics (U.S.) Business Overview
11.18.3 Synthetic Biologics (U.S.) IBS Treatment Introduction
11.18.4 Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.18.5 Synthetic Biologics (U.S.) Recent Development
11.19 Protagonist Therapeutics (U.S.)
11.19.1 Protagonist Therapeutics (U.S.) Company Detail
11.19.2 Protagonist Therapeutics (U.S.) Business Overview
11.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Introduction
11.19.4 Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.19.5 Protagonist Therapeutics (U.S.) Recent Development
11.20 Pfizer (U.S.)
11.20.1 Pfizer (U.S.) Company Detail
11.20.2 Pfizer (U.S.) Business Overview
11.20.3 Pfizer (U.S.) IBS Treatment Introduction
11.20.4 Pfizer (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.20.5 Pfizer (U.S.) Recent Development
11.21 Lexicon Pharmaceuticals (U.S.)
11.21.1 Lexicon Pharmaceuticals (U.S.) Company Detail
11.21.2 Lexicon Pharmaceuticals (U.S.) Business Overview
11.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Introduction
11.21.4 Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.21.5 Lexicon Pharmaceuticals (U.S.) Recent Development
11.22 Innovate Biopharmaceuticals (U.S.)
11.22.1 Innovate Biopharmaceuticals (U.S.) Company Detail
11.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
11.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
11.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022)
11.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global IBS Treatment Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of IBS-D
Table 3. Key Players of IBS-C
Table 4. Key Players of IBS-M
Table 5. Global IBS Treatment Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global IBS Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global IBS Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global IBS Treatment Market Share by Region (2017-2022)
Table 9. Global IBS Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global IBS Treatment Market Share by Region (2023-2028)
Table 11. IBS Treatment Market Trends
Table 12. IBS Treatment Market Drivers
Table 13. IBS Treatment Market Challenges
Table 14. IBS Treatment Market Restraints
Table 15. Global IBS Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global IBS Treatment Market Share by Players (2017-2022)
Table 17. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2021)
Table 18. Ranking of Global Top IBS Treatment Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by IBS Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players IBS Treatment Product Solution and Service
Table 22. Date of Enter into IBS Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global IBS Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global IBS Treatment Revenue Market Share by Type (2017-2022)
Table 26. Global IBS Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global IBS Treatment Revenue Market Share by Type (2023-2028)
Table 28. Global IBS Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global IBS Treatment Revenue Market Share by Application (2017-2022)
Table 30. Global IBS Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global IBS Treatment Revenue Market Share by Application (2023-2028)
Table 32. North America IBS Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America IBS Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe IBS Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe IBS Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific IBS Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific IBS Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America IBS Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America IBS Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa IBS Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa IBS Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 42. Allergan (Ireland) Company Detail
Table 43. Allergan (Ireland) Business Overview
Table 44. Allergan (Ireland) IBS Treatment Product
Table 45. Allergan (Ireland) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 46. Allergan (Ireland) Recent Development
Table 47. Sucampo Pharmaceuticals (U.S.) Company Detail
Table 48. Sucampo Pharmaceuticals (U.S.) Business Overview
Table 49. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product
Table 50. Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 51. Sucampo Pharmaceuticals (U.S.) Recent Development
Table 52. Ironwood Pharmaceuticals (U.S.) Company Detail
Table 53. Ironwood Pharmaceuticals (U.S.) Business Overview
Table 54. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product
Table 55. Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 56. Ironwood Pharmaceuticals (U.S.) Recent Development
Table 57. Astellas Pharma (Japan) Company Detail
Table 58. Astellas Pharma (Japan) Business Overview
Table 59. Astellas Pharma (Japan) IBS Treatment Product
Table 60. Astellas Pharma (Japan) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 61. Astellas Pharma (Japan) Recent Development
Table 62. Bausch Health Company Detail
Table 63. Bausch Health Business Overview
Table 64. Bausch Health IBS Treatment Product
Table 65. Bausch Health Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 66. Bausch Health Recent Development
Table 67. Abbott Laboratories (U.S.) Company Detail
Table 68. Abbott Laboratories (U.S.) Business Overview
Table 69. Abbott Laboratories (U.S.) IBS Treatment Product
Table 70. Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 71. Abbott Laboratories (U.S.) Recent Development
Table 72. Synergy Pharmaceuticals (U.S.) Company Detail
Table 73. Synergy Pharmaceuticals (U.S.) Business Overview
Table 74. Synergy Pharmaceuticals (U.S.) IBS Treatment Product
Table 75. Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 76. Synergy Pharmaceuticals (U.S.) Recent Development
Table 77. Ardelyx (U.S.) Company Detail
Table 78. Ardelyx (U.S.) Business Overview
Table 79. Ardelyx (U.S.) IBS Treatment Product
Table 80. Ardelyx (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 81. Ardelyx (U.S.) Recent Development
Table 82. Nestle (Switzerland) Company Detail
Table 83. Nestle (Switzerland) Business Overview
Table 84. Nestle (Switzerland) IBS Treatment Product
Table 85. Nestle (Switzerland) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 86. Nestle (Switzerland) Recent Development
Table 87. Sebela Pharmaceuticals (Ireland) Company Detail
Table 88. Sebela Pharmaceuticals (Ireland) Business Overview
Table 89. Sebela Pharmaceuticals (Ireland) IBS Treatment Product
Table 90. Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 91. Sebela Pharmaceuticals (Ireland) Recent Development
Table 92. Probi (Sweden) Company Detail
Table 93. Probi (Sweden) Business Overview
Table 94. Probi (Sweden) IBS TreatmentProduct
Table 95. Probi (Sweden) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 96. Probi (Sweden) Recent Development
Table 97. Alfasigma USA (Italy) Company Detail
Table 98. Alfasigma USA (Italy) Business Overview
Table 99. Alfasigma USA (Italy) IBS TreatmentProduct
Table 100. Alfasigma USA (Italy) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 101. Alfasigma USA (Italy) Recent Development
Table 102. RedHill Biopharma (Israel) Company Detail
Table 103. RedHill Biopharma (Israel) Business Overview
Table 104. RedHill Biopharma (Israel) IBS TreatmentProduct
Table 105. RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 106. RedHill Biopharma (Israel) Recent Development
Table 107. AstraZeneca (U.K) Company Detail
Table 108. AstraZeneca (U.K) Business Overview
Table 109. AstraZeneca (U.K) IBS TreatmentProduct
Table 110. AstraZeneca (U.K) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 111. AstraZeneca (U.K) Recent Development
Table 112. Ipsen (France) Company Detail
Table 113. Ipsen (France) Business Overview
Table 114. Ipsen (France) IBS TreatmentProduct
Table 115. Ipsen (France) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 116. Ipsen (France) Recent Development
Table 117. Novartis (Switzerland) Company Detail
Table 118. Novartis (Switzerland) Business Overview
Table 119. Novartis (Switzerland) IBS TreatmentProduct
Table 120. Novartis (Switzerland) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 121. Novartis (Switzerland) Recent Development
Table 122. Takeda Pharmaceutical Company (Japan) Company Detail
Table 123. Takeda Pharmaceutical Company (Japan) Business Overview
Table 124. Takeda Pharmaceutical Company (Japan) IBS TreatmentProduct
Table 125. Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 126. Takeda Pharmaceutical Company (Japan) Recent Development
Table 127. Synthetic Biologics (U.S.) Company Detail
Table 128. Synthetic Biologics (U.S.) Business Overview
Table 129. Synthetic Biologics (U.S.) IBS TreatmentProduct
Table 130. Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 131. Synthetic Biologics (U.S.) Recent Development
Table 132. Protagonist Therapeutics (U.S.) Company Detail
Table 133. Protagonist Therapeutics (U.S.) Business Overview
Table 134. Protagonist Therapeutics (U.S.) IBS TreatmentProduct
Table 135. Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 136. Protagonist Therapeutics (U.S.) Recent Development
Table 137. Pfizer (U.S.) Company Detail
Table 138. Pfizer (U.S.) Business Overview
Table 139. Pfizer (U.S.) IBS TreatmentProduct
Table 140. Pfizer (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 141. Pfizer (U.S.) Recent Development
Table 142. Lexicon Pharmaceuticals (U.S.) Company Detail
Table 143. Lexicon Pharmaceuticals (U.S.) Business Overview
Table 144. Lexicon Pharmaceuticals (U.S.) IBS TreatmentProduct
Table 145. Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 146. Lexicon Pharmaceuticals (U.S.) Recent Development
Table 147. Innovate Biopharmaceuticals (U.S.) Company Detail
Table 148. Innovate Biopharmaceuticals (U.S.) Business Overview
Table 149. Innovate Biopharmaceuticals (U.S.) IBS TreatmentProduct
Table 150. Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2017-2022) & (US$ Million)
Table 151. Innovate Biopharmaceuticals (U.S.) Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global IBS Treatment Market Share by Type: 2021 VS 2028
Figure 2. IBS-D Features
Figure 3. IBS-C Features
Figure 4. IBS-M Features
Figure 5. Global IBS Treatment Market Share by Application in 2021 & 2028
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Research Laboratories Case Studies
Figure 9. IBS Treatment Report Years Considered
Figure 10. Global IBS Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global IBS Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global IBS Treatment Market Share by Region: 2021 VS 2028
Figure 13. Global IBS Treatment Market Share by Players in 2021
Figure 14. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by IBS Treatment Revenue in 2021
Figure 16. North America IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America IBS Treatment Market Share by Country (2017-2028)
Figure 18. United States IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe IBS Treatment Market Share by Country (2017-2028)
Figure 22. Germany IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific IBS Treatment Market Share by Region (2017-2028)
Figure 30. China IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America IBS Treatment Market Share by Country (2017-2028)
Figure 38. Mexico IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa IBS Treatment Market Share by Country (2017-2028)
Figure 42. Turkey IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia IBS Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Allergan (Ireland) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 45. Sucampo Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 46. Ironwood Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 47. Astellas Pharma (Japan) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 48. Bausch Health Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 49. Abbott Laboratories (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 50. Synergy Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 51. Ardelyx (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 52. Nestle (Switzerland) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 53. Sebela Pharmaceuticals (Ireland) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 54. Probi (Sweden) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 55. Alfasigma USA (Italy) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 56. RedHill Biopharma (Israel) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 57. AstraZeneca (U.K) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 58. Ipsen (France) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 59. Novartis (Switzerland) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 60. Takeda Pharmaceutical Company (Japan) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 61. Synthetic Biologics (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 62. Protagonist Therapeutics (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 63. Pfizer (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 64. Lexicon Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 65. Innovate Biopharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Allergan (Ireland) Sucampo Pharmaceuticals (U.S.) Ironwood Pharmaceuticals (U.S.) Astellas Pharma (Japan) Bausch Health Abbott Laboratories (U.S.) Synergy Pharmaceuticals (U.S.) Ardelyx (U.S.) Nestle (Switzerland) Sebela Pharmaceuticals (Ireland) Probi (Sweden) Alfasigma USA (Italy) RedHill Biopharma (Israel) AstraZeneca (U.K) Ipsen (France) Novartis (Switzerland) Takeda Pharmaceutical Company (Japan) Synthetic Biologics (U.S.) Protagonist Therapeutics (U.S.) Pfizer (U.S.) Lexicon Pharmaceuticals (U.S.) Innovate Biopharmaceuticals (U.S.)